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Background: Tuberculosis (TB) is the second leading cause of death from a single infectious organism, demanding
attention towards discovery of novel anti-tubercular compounds. Natural products or their derivatives have
provided more than 50% of all existing drugs, offering a chemically diverse space for discovery of novel drugs.
Description: BioPhytMol has been designed to systematically curate and analyze the anti-mycobacterial natural
product chemical space. BioPhytMol is developed as a drug-discovery community resource with anti-mycobacterial
phytomolecules and plant extracts. Currently, it holds 2582 entries including 188 plant families (692 genera and 808
species) from global flora, manually curated from literature. In total, there are 633 phytomolecules (with structures)
curated against 25 target mycobacteria. Multiple analysis approaches have been used to prioritize the library for
drug-like compounds, for both whole cell screening and target-based approaches. In order to represent the
multidimensional data on chemical diversity, physiochemical properties and biological activity data of the
compound library, novel approaches such as the use of circular graphs have been employed.
Conclusion: BioPhytMol has been designed to systematically represent and search for anti-mycobacterial phytochemical
information. Extensive compound analyses can also be performed through web-application for prioritizing drug-like
compounds. The resource is freely available online at http://ab-openlab.csir.res.in/biophytmol/.
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According to the WHO Global Tuberculosis report, 2013,
TB alone was responsible for nearly 1.3 million deaths and
8.6 million new cases in 2012 [1]. The current TB treat-
ment regimen is lengthy and multi-therapy based. Over
time, TB causing bacteria i.e., Mycobacterium tuberculosis
(Mtb) has acquired resistance against existing antibiotics
leading to multi-drug resistant (MDR), extensively drug
resistant (XDR) and totally drug-resistant (TDR) forms [2].
The long-duration therapies also possess various side-
effects and toxicity issues [3]. Bedaquiline has been recently
approved by United States Food and Drug Administration
(FDA) in December 2012, almost after 50 years of the* Correspondence: anshub@osdd.net
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reproduction in any medium, provided the odiscovery of the last anti-tubercular (anti-TB) drug. This
drug comes with a black box warning of induction of
arrhythmia followed by the risk of developing resistance if
used improperly [4]. There are other anti-TB drugs too in
various stages of development [3-5]. However, there is a
need to discover novel, highly effective, less-toxic anti-TB
drugs having new mechanism of action. There is an
increasing demand to explore new chemical space given
the emergence of drug-resistance even for newly developed
therapies. Exploring natural product (NP) space may prove
to be a valuable source of new and less-toxic anti-TB drugs
[5,6]. Analysis of the NP chemical space has led to the
identification of novel scaffolds [7] and increased chance of
discovering compounds possessing novel mechanism of
action [8]. The overall chemical space covered by synthetic
compounds is limited as compared to natural com-
pounds given their higher chemical diversity [9]. Moreis an Open Access article distributed under the terms of the Creative Commons
org/licenses/by/4.0), which permits unrestricted use, distribution, and
riginal work is properly credited.
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or NP derivatives [10]. For example, the recent FDA
approved drug, Fulyzaq (http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm333701.htm), is the
first anti-diarrheal drug for adult HIV/AIDS patients
derived from the plant Croton lechleri. Also, of
currently known 28 anti-TB drugs [2], eight drugs i.e.,
Rifampicin, Rifapentine, Streptomycin, Kanamycin,
Amikacin, Capreomycin, Viomycin and Cycloserine
have been derived from microbial sources (NPs) (see
Additional file 1: Table S1). Many experimentally
tested anti-mycobacterial NPs are scattered through-
out scientific literature [11,12]. In order to systematic-
ally evaluate their anti-mycobacterial properties, this
data needs to be systematically collated and analyzed.
A number of pathway and cheminformatics tools for TB
drug discovery have been developed but are not exclusively
for plant derived anti-mycobacterial compounds [13,14]. At
present, Universal Natural Products Database (UNPD) is
the largest freely available resource for NPs and holds a
total of 197201 NPs of plants, animals and microbial origin
[15]. The various other NP databases and chemical libraries
freely available for public use are NuBBE [16], CamMedNP
[17], SuperNatural [18], HIT [19], NPACT [20], TCM
Database@Taiwan [21], TCMID [22], HIM-herbal ingredi-
ents in-vivo metabolism database [23], AfroDB [24] and
ConMedNP [25], to name a few. However, information
related to phytomolecules and plant extracts against
mycobacterial strains is very limited. Moreover, such data
resources should be equipped with analysis tools to
prioritize compounds for early stage drug discovery,
which is missing. Furthermore, all the resources may
follow a standardized global ontology so that the data
shared by individuals or laboratories is interoperable and
facilitate implementation of the semantic web features.
BioPhytMol has been developed as a database cum drug
discovery platform that can be used to prioritize drug-like
compounds. A number of experimentally verified anti-
mycobacterial phytomolecules along with their experimen-
tal assay preparation and bioactivity details have been
manually compiled from literature. Tools providing text
searching, browsing and chemical similarity searching for
phytomolecules have been integrated to utilize BioPhytMol
as a drug discovery platform. The chemical structure
similarity tool can be exploited to perform exact, substruc-
ture, superstructure and perfect search against various
drug-like chemical libraries. This facility may be helpful to
assign chemical classes and bioactivity to novel com-
pounds. Users can also generate analogs for their target
specific inhibitors. As of now the resource holds a total of
2582 entries including 188 plant families (comprised of
692 genera and 808 species) from global flora. In total, 633
purified compounds have been curated against 25 different
target mycobacteria. These are reported along with theirbiological activity and experimental details as described
below. The resource is available at http://ab-openlab.csir.
res.in/biophytmol/.Construction and content
Data source and structure
The PubMed literature database (http://www.ncbi.nlm.
nih.gov/pubmed) and Google search (https://www.google.
com/) were considered as major sources for collecting the
plant derived anti-mycobacterial compounds and extracts.
Initially, the relevant papers were downloaded using
keywords such as ‘natural product’, ‘plant product’, ‘anti-tu-
berculosis’, ‘anti-mycobacterial’, ‘Mycobacterium tubercu-
losis’, ‘TB’ and ‘Mtb’. Papers with TB and natural product/
plant product keywords in their abstract were further short-
listed. More than 150 research articles/reviews were used to
retrieve anti-mycobacterial phytomolecules and plant ex-
tracts. A well-defined data structure (Additional file 1:
Table S2) was followed to systematically extract, capture
and store data manually for purified anti-mycobacterial
phytomolecules and plant extracts. Wherever avail-
able, a PubChem ID (http://pubchem.ncbi.nlm.nih.
gov/) has been assigned to purified phytomolecule. To
maintain a common standard, wherever the activity was
given in terms of μM, it was converted to μg/ml using
GraphPad (http://www.graphpad.com/quickcalcs/Molarity-
form/). The structures unavailable in PubChem were
drawn manually using MarvinSketch 5.11.4 software from
ChemAxon (http://www.chemaxon.com/products/marvin/
marvinsketch/) and were assigned a BioPhytMol ID.Data curation
The data was manually curated using a structured-wiki
platform. To perform data quality check, a semi-automated
procedure was followed based on a well-defined data struc-
ture as mentioned earlier. A set of dedicated curators also
checked the data manually and well-curated data was finally
stored in MySQL, an open-source relational database
management system (RDBMS). For both data capture and
curation, crowdsourcing through online platforms have
been implemented. Each database entry is tagged with the
contributor’s details.Platform architecture
BioPhytMol database has been developed using open
source software LAMP (Linux-Apache-Mysql-PHP) server
technology. PHP, HTML, JavaScript, AJAX and CSS
technologies have been used to build the web interface.
The whole software system runs on IBM SAS x3800
machine under Red Hat Enterprise Linux 5 environment
using Apache httpd server.
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User interface
The interface of BioPhytMol platform is customized to
query the database with various searches and browse
options. It is also bundled with various analysis tools to
facilitate analysis of new compounds. In addition to
this, the interface provides a link to update the data-
base using a submission form. It also lists the database
statistics along with physicochemical properties of the
compounds. The data structure of the database and
link to relevant TB and NP resources are also incorpo-
rated in BioPhytMol. The ‘BioPhytMol Help’ option
has been used to explain how to use the platform. The
homepage of the website has been shown in Additional
file 1: Figure S1.
Search tools
Three search options are provided on the web interface
namely ‘Simple Search’, ‘Query Builder’ and ‘Structure
Search’. Simple Search option allows users to perform
text-based search on all/selected field of the database.
Overall, the database contains 35 unique fields as shown
in Figure 1.
Some of the major fields are (i) Compound ID (ii)
Compound Structure (iii) Plant Source (iv) Source Family
(v) Geographical Origin (vi) Plant Part Used (vii) Extract
(vii) Target Bacteria (viii) Positive Control Used (ix) % in-
hibition (x) Activity [MIC] in μg/ml (xi) Active Compound
Identified (xii) PubChem ID (xiii) Extract Preparation (xiv)
Chemical Classification (xv) Media/Broth Used (xvi) Cyto-
toxicity Assay, etc. (See Additional file 1: Table S2 for
details). User can display any or all fields of database for
selected searched records.
The Query Builder option facilitates querying the
database through complex queries with the help of
logical operators such as AND & OR. This option helps
to retrieve refined results, most relevant to user's query,
such as compounds having molecular weight within a
particular range, compounds having specific minimum
inhibitory concentration (MIC) or following Lipinski’s rule
of five [26], etc.
An extensive ‘Structure Search’ interface has been
designed that allows users to find similar compounds
from all/any of the drug-like classes by either drawing
the structure, through SMILES format or uploading
the chemical structure in SDF, MOL or MOL2 formats. In
order to draw structures to be searched, a simple Java
based applet - Java Molecular Editor (JME) (http://www.
molinspiration.com/jme/) has been incorporated. A variety
of structure search methods such as substructure, super-
structure, exact and similarity based search have been
provided. Users can perform structure based searches
against BioPhytMol compounds (B_mols)/Anti-TB drugs
(A_tb) and various DrugBank compound classes such asFDA approved small molecule drugs (FDA_small), FDA
approved nutraceutical drugs (FDA_nutra), experimental,
withdrawn and illicit drugs. The Structure Search is
performed using jcsearch [27] that provides various search-
ing options as mentioned above. Additional file 1: Figure S2
depicts the structure search tool provided in the resource.Browsing interface
The browsing interface provides an easy way to explore
the BioPhytMol resource. Phytomolecules can be browsed
using their physicochemical properties that include mol-
ecular weight, XLogP, polar surface area (PSA), hydrogen
bond donor (HBD), hydrogen bond acceptor (HBA), num-
ber of Oxygen, Nitrogen and Sulphur atoms, number of
rings and number of rotatable bonds. The major fields of
database that can be browsed are shown in Figure 1. All the
numerical fields can be sorted while browsing.Tools used for compound analysis and clustering
A set of tools and algorithms has been used for compound
analysis in BioPhytMol. For detecting near neighbours
(NNs), NNeib (version 5.12.0) (https://docs.chemaxon.
com/display/jklustor/Jarvis-Patrick+clustering) was used.
Clustering of B_mols was done using Jarp (version 6.0.2)
from ChemAxon that follows variable length Jarvis-Patrick
clustering algorithm (https://docs.chemaxon.com/display/
jklustor/Jarvis-Patrick+clustering). Jarp uses the nearest
neighbours information of the compounds in order to
assign them into clusters based on dissimilarity threshold
(i.e. 1-tanimoto coefficient). To compute the dissimilarity
threshold, Jarp refers to the propriety chemical structure
fingerprints calculated using ‘generatemd’ program of
ChemAxon. These fingerprints are then used by NNeib pro-
gram for calculating nearest neighbours using the
dissimilarity threshold which is further used by the Jarp pro-
gram of ChemAxon for assigning compounds into clusters.
Detailed information can be found at: https://docs.chemaxon.
com/display/jklustor/Jarvis-Patrick+clustering. A threshold of
0.15 is used as the dissimilarity threshold for clustering
compounds. A total of 10 descriptors were calculated
using PowerMV [28] descriptor calculator software
namely molecular weight, XLogP, PSA, H-bond Donor,
H-bond Acceptor, number of Rotatable Bond Count,
number of rings, number of nitrogen atoms, number of
oxygen atoms and number of sulphur atoms.
Molecular formula of each compound was calculated
using ChemAxon’s command line program ‘cxcalc’
(version 5.12.0) (https://docs.chemaxon.com/display/
CALCPLUGS/cxcalc+command+line+tool). To check for
compound’s drug-likeness, a variety of filters were applied
using DruLiTo (http://www.niper.gov.in/pi_dev_tools/
DruLiToWeb/DruLiTo_index.html).
Figure 1 BioPhytMol database architecture showing its various components with ‘Search’ options, ‘Browse by’ options and structural
‘similarity’ between BioPhytMol compounds and Anti-TB drugs, FDA approved small molecule drugs and Nutraceuticals.
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BioPhytMol facilitates the users to display 2-D and 3-D
structure of molecules using images and Jmol (http://www.
jmol.org/), respectively. Wordle (http://www.wordle.net/)
(developed by Jonathan Feinberg), was used to develop the
tag cloud of various chemical classes of B_mols. For the
first time, we have customized CIRCOS [29] (http://circos.
ca/) to visualize multiple chemical properties with bio-
logical activity and obtain clusters for near neighbour
analysis. CIRCOS is originally designed for visualization of
genomic data in the form of circular layout (graph) and
hence the configuration and data files represent data in
context of chromosome positions. The karyotype file in
CIRCOS package is used to define the data points on this
circular graph. The same concept has been translated to
visualization of chemical and biological data associated with
B_mols. In this study, 633 data points were defined (bands)
with each band having a width of 1000. This baseline is
then used to highlight cyclic and aliphatic compounds. Fur-
ther customization needs appropriate modifications to gen-
erate corresponding histogram files. For better visualization
of nature of relationship amongst members of clusters
a compound network diagram (CND) was made using
Cytoscape (http://www.cytoscape.org/).
BioPhytMol statistics
At present, BioPhytMol resource holds a total of 2582
entries including 188 plant families (comprised of 692genera and 808 species) from global flora. In total, 633
purified compounds have been curated against 25 differ-
ent target mycobacteria. These B_mols are reported along
with their biological activity and experimental details
including the assay performed, target bacteria, positive
control, etc. Of the 633 compounds, 125 (20%) listed in
BioPhytMol have more than one MIC reported against
them. The remaining 495 (~78%) compounds have single
MIC values and 13 B_mols have no MIC data. The
geographical distribution of plants shows that majority
of anti-mycobacterial phytomolecules/plant extracts are
from Indian origin followed by Africa, Mexico, Peru
and Malaysia (http://ab-openlab.csir.res.in/biophytmol/
browse_origin.php?f=origin). Additional file 1: Figure S3
shows the distribution of plants among top 35 plant fam-
ilies present in the resource with Asteraceae, Fabaceae
and Rutaceae having more than hundred plants each.
‘Asteraceae’ has the highest number of entries (215) in
the resource. Helichrysum melanacme, a plant from
Asteraceae family, showed the lowest MIC against Mtb at
0.05 μg/ml. From the same family, Chrysanthemum mori-
folium produces the highest number of anti-mycobacterial
compounds with varying range of MICs (4–64 μg/ml). For
example, 3-Epilupeol was active against Mtb at 4 μg/ml,
while Calenduladiol was active against Mtb at 64 μg/ml.
From Additional file 1: Figure S3, it is also observed that
there are families which contain less than 25 plants.
Cordia globifera from ‘Boraginaceae’ family was reported
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be noted that highly potent anti-mycobacterial com-
pounds may be present in other plant families too.
Hence, underrepresented families in our database may
be further explored to find new plants with anti-
mycobacterial properties.
Diversity in B_mols
Clustering of 633 B_mols produced a total of 423 clusters
of which 318 clusters (50.24% of B_mols) were singletons
while remaining 105 clusters (49.76% of B_mols) were
non-singletons (see Additional file 1: Figure S4). This indi-
cates that BioPhytMol library is chemically diverse. For
better visualization of the nature of relationship amongst
members of the clusters, the CND generated using
Cytoscape may be seen at http://ab-openlab.csir.res.in/
biophytmol/circos.php. The nodes in the CND are color
coded with blue color representing active compounds, red
representing inactive compounds and yellow is where MIC
data is unavailable. A threshold MIC of > =200 μg/ml is
used for segregating active B_mols and inactive B_mols.
This threshold classifies 633 B_mols into 582 active com-
pounds (MIC < 200 μg/ml), 38 inactive compounds while
MIC values were unavailable for 13 B_mols. As can be seen
from the CND (http://ab-openlab.csir.res.in/biophytmol/
circos.php), only 14 inactive compounds cluster with 301
active compounds in 105 clusters. A table with compounds
in each cluster is provided along with the CND for better
interpretation of the data (http://ab-openlab.csir.res.in/
biophytmol/circos.php#biophyt_clusters).
CIRCOS visualization and analysis of chemical and
biological properties
As discussed, BioPhytMol resource includes chemical
details and biological data for the phytomolecules. The
chemical details include structure, physicochemical prop-
erties and near neighbours. The biological data includes
mycobacterial growth % inhibition and MIC of these
compounds. Attempt has been made to represent this
multidimensional data through circular graphs using CIR-
COS. The overall distribution of important physicochemical
properties of B_mols with biological data is depicted in
Figure 2.
The outermost ring represents the broad chemical
structures of the compounds indicating that majority of
the compounds are cyclic in nature. The next ring depicts
the biological activity of the compounds with MIC ≤ 50
μg/ml and % inhibition > 90. The subsequent rings repre-
sent six graphs of calculated physicochemical properties
namely molecular weight, hydrogen bond acceptor, hydro-
gen bond donor, XLogP, polar surface area and number of
rotatable bonds. All 633 compounds were sorted in the in-
creasing order of their molecular weight. Compounds with
molecular weight > 900 Daltons (Da) (10 compounds)were removed subjectively and are not represented in the
CIRCOS plot and thus, only 623 compounds have been
used to plot Figure 2. A list of another six CIRCOS plots
sorted on the basis of six physicochemical properties,
namely, molecular weight, XLogP, number of hydrogen
bond donors, number of hydrogen bond acceptors, polar
surface area and number of rotatable bonds, are provided
on the BioPhytMol platform (http://ab-openlab.csir.res.in/
biophytmol/circos.php#biophyt_circos). Each physicochem-
ical property was sorted to retrieve six different CIRCOS
plots. Outliers were removed from sorted physicochemical
property data before generating the plots. The following
formula was used to remove the outliers:
Q1‐k Q3‐Q1ð Þ;Q3þk Q3‐Q1ð Þ½ 
Where Q1 and Q3 are the first and third quartile re-
spectively and k is the constant (default value of k =1.5).
The above formula gives a range in the data. Any value
outside this range in the data is taken as an outlier.
The innermost graph in Figure 2 (sorted on molecular
weight) represents the near neighbours amongst B_mols.
It is interesting to observe in some cases that compounds
that span different molecular weight range are near neigh-
bours. For example, T-cadinol (22.198 Da) has three near
neighbours: Maniladiol (442.381 Da), Faradiol (442.381
Da) and Erythrodiol (442.381 Da). Presence of certain
structural features in ‘Maniladiol’ may be responsible for
its better anti-mycobacterial activity against Mtb H37Rv
(4 μg/ml) as compared to T-cadinol, Faradiol and Erythro-
diol (16–64 μg/ml). Hence, this approach is useful in
finding out pharmacophoric features that may be import-
ant in contributing to the anti-mycobacterial property of a
particular compound. At least twenty cases have been
observed where the nearest neighbours have shown large
difference in their MIC values. For example, N-trans-
Feruloyltyramine (Additional file 1: Figure S5 A) and Feru-
loyltyramine (Additional file 1: Figure S5 B) were active
against Mtb H37Rv at an MIC of 128 μg/ml and 1.6 μg/ml
respectively. An additional methoxy group (−OCH3) in
Feruloyltyramine (as depicted in Additional file 1: Figure
S5 C by dotted circle) may be responsible for defining the
pharmacophoric feature of the compound.
Physicochemical distribution of B_mols with respect to
FDA_small, FDA_Nutra and A_tb
To estimate the oral bioavailability and drug-likeness of
B_mols, these were filtered on the basis of physicochemi-
cal properties as suggested by Lipinski and Veber [30].
Also, physicochemical distribution, as followed by ≥ 70%
FDA approved drugs, was taken into account simultan-
eously. Of 633 phytomolecules, 232 passed these filters
(http://ab-openlab.csir.res.in/biophytmol/extract_fda_oral.
php). Physicochemical properties of the entire B_mols
Figure 2 Overall distribution of chemical, biological and physicochemical properties of 623 BioPhytMol phytomolecules. The outermost
circle represents the broad chemical structure of compounds i.e., they are cyclic or aliphatic. The next ring depicts the biological activity of the
compounds in terms of MIC ≤ 50 μg/ml and mycobacterial growth % inhibition > 90. The subsequent rings represent six graphs of calculated
physicochemical properties. All the compounds are sorted in the increasing order of their molecular weight. The innermost graph is the
representation of near neighbours (NN) amongst B_mols. The four compounds: T-cadinol, Maniladiol, Faradiol and Erythrodiol are nearest neighbours
with difference in molecular weight between T-cadinol and the rest of the three compounds. Important structural differences may be the reason
behind different MICs.
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and A_tb. It was observed that the highest peak for mo-
lecular weight of B_mols lie within 201–300 (Additional
file 1: Figure S6 A). This is in accordance with both
Lipinski rule of 5 and Lipinski rule of 3 for antibacterial
compounds [31].
Number of HBD for B_mols showed highest peak in
the range of 1–3 (Additional file 1: Figure S6 B). Similar
trend was observed for rest of the drug classes. As for
HBA, majority B_mols, A_tb and FDA_nutra lied in the
range of 1–3 (Additional file 1: Figure S6 C). In the case
of XLogP, a high peak was observed in the case of
B_mols, FDA_small and A_tb which was in the range of
4–7 (Additional file 1: Figure S6 D). PSA and number of
rotatable bonds are good physicochemical property to
predict oral bioavailability of a drug. In past, it has been
observed that compounds having PSA ≤ 140 Å2 andnumber of rotatable bonds ≤ 10 possess higher probabil-
ity of good oral bioavailability [30]. The highest peak of
B_mols for PSA and number of rotatable bonds lie
between 51–100 Å2 (Additional file 1: Figure S6 E) and
1–3 (Additional file 1: Figure S6 F), respectively.
Structural similarity of B_mols with existing drugs
Using NNs search, B_mols similar to A_tb, FDA_nutra and
FDA_small have been identified. The result of this NNs search
is reported in two sections under 'Similarity' option: (i) One to
one; (ii) One to many. In ‘One to one’, B_mol is shown paired
with its similar drug and calculated dissimilarity threshold
value for that pair, e.g., four B_mols showed similarity with
Amikacin (a second-line anti-TB drug) and six B_mols
showed similarity with Clarithromycin (third-line anti-TB
drug) at 0.4 dissimilarity threshold (http://ab-openlab.csir.
res.in/biophytmol/str_stats_man.php). These B_mols may
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on this prioritization, they may be further experimentally
tested for anti-TB activity in-vitro and in-vivo.
Owing to wide range of indications covered by
nutraceuticals such as less toxicity, physiological
health benefits and good oral bioavailability, they are
gaining popularity as promising drug candidates [32].
NNs search of B_mols against FDA_nutra resulted into identi-
fication of four phytomolecules (http://ab-openlab.csir.res.in/
biophytmol/fda_nutra.php). For example, Stigmasta-4-22-
dien-3-one (BioPhytMol ID - 2205) active against Mtb at < 2
μg/ml, is a phytomolecule (extracted from leaf of Morinda
citrifolia L.) that showed structural similarity with 19-
norandrostenedione (DrugBank ID - DB01434), once mar-
keted as a dietary supplement. Overall, there are 10, 4 and 16
B_mols similar to 2A_tb, 4 FDA_nutra and 15 FDA_small, re-
spectively (see Additional file 1: Table S3).Drug-likeness of B_mols
To prioritize drug-like phytomolecules, DruLiTo software
was used to screen molecules based on eight filters namely
Lipinski's rule, MDDR-like rule, Veber rule, Ghose filter,
BBB rule, CMC-50 like rule, weighted and unweighted
Quantitative Estimate of Drug-likeness [33-35]. As evident
from Figure 3A, six of 633 compounds passed all eight
filters.
It was also noticed that out of these six compounds, three
compounds i.e., Figure 3B 4–6, had a Michael acceptor
moiety (double bond next to a carbonyl group, highlighted
by dotted circle) (http://bioserv.rpbs.univ-paris-diderot.fr/
FAF-Drugs/). The presence of this functional group makes
the compound ‘non-leadlike’ which gives false positive
results in biochemical assays. Hence, filters for drug-
likeness are not enough to state that the compounds will
be successful in further drug discovery stages, but identifi-
cation of such ‘warhead agents’, ‘frequent hitter’ and ‘pro-
miscuous inhibitors’ are important to evaluate the chances
of success for a particular scaffold in a drug discovery
process [36].
In a recent study published by GSK, 177 anti-TB hits
with low in-vitro cytotoxicity were reported [37]. On com-
parison of 633 B_mols with 177 hits, 20 B_mols showed
similarity with two GSK compounds. Of these 20 B_mols,
6 were similar to GSK compound GSK146660A and 14
were similar to GSK1996236A. These compounds are
predicted to act via Rv0458, Rv0548c, Rv1747, Rv2971 and
Rv3170 [38]. Additional file 1: Table S4 can be seen for
complete details.
This approach could be used to identify putative targets
for other B_mols/novel compounds where target informa-
tion is missing. Another freely available target identification
tool published recently includes TB Mobile 2.0 which iden-
tifies potential targets based on molecular similarity [39].Alternatively, one can also assess the target specific inhibi-
tors for their activity in whole cell screens.
Natural products ontology and chemical classification
Presence of a universal ontology is necessary for global un-
derstanding of NP data. National Center for Biomedical
Ontology (NCBO) has developed one such ontology for
NPs- the Natural products Ontology (NATPRO) (http://
bioportal.bioontology.org/ontologies/NATPRO). Of 35 Bio-
PhytMol metadata, 12 mapped to various levels in NAT-
PRO metadata (see Additional file 1: Table S5). However,
the chemical classification of NATPRO was not sufficient
to broadly classify the compounds.
Classification of chemical compounds aids the evaluation
and abstraction of compound properties. In addition, it
may enable new ways of knowledge discovery for example
by extracting relationships between compound structure
and its properties, traditionally known as structure-activity
relationships (SAR) or structure property relationships
(SPR). The basic idea behind this classification is to be able
to connect the properties of the compounds with their
biological activity. The compounds have been classified
broadly into three levels. In the primary level, the com-
pounds were classified into aromatic (312), alicyclic (274)
and aliphatic (46) compounds. One compound was classi-
fied as a mixture. At the secondary level, each of the three
classes are further divided based on presence of specific
groups (e.g., Aryl group), no. of carbon-carbon bonds (e.g.,
alkane, alkene or alkyne) and no. of cycles. In the tertiary
level, the classification is based on functional groups like
alcohol, ketone, aldehyde, ester, etc. and broad classes like
steroid, terpene, triterpene, sesquiterpene, sugar, furan, etc.
Additional file 1: Figure S7 shows an example of an
aromatic compound containing ether, phenol and ke-
tone as functional groups and it belongs to two classes
i.e. chalcone and sugar. In the browse page of BioPhyt-
Mol website, prominent classes in BioPhytMol have
been shown as a tag-cloud (http://ab-openlab.csir.res.
in/biophytmol/browse.php). From the tag-cloud, it can
be seen that majority of the B_mols are aromatic (312)
in nature with many compounds having phenol (176
compounds) and ether (161) as functional groups. The
complete chemical classification of B_mols can be
found from the link given below: http://ab-openlab.csir.
res.in/biophytmol/browse.php?f=chem_class.
Discussion
BioPhytMol is a drug-discovery community resource
with a database of anti-mycobacterial phytomolecules
and plant extracts with analysis tools integrated into a
web-application. The database is based on extensive litera-
ture search and curation and is the only searchable resource
on anti-mycobacterial phytomolecules. In addition to the
data on plant extracts or the purified active ingredients, the
Figure 3 Drug-likeness study of BioPhytMol compounds. (A) Compound distribution graph based on the number of compounds screened
against DruLiTo (Drug-likeness Tool) filter with 6 compounds passing all 8 filters. (B) Structure of BioPhytMol compounds crossing all the filters of
DruLiTo: (1) 4-((Z)-2-(3-(3,4-dimethoxystyryl)isoxazol-5-yl)vinyl)-2-methoxyphenol (2) 4-((E)-2-(5-(3,4-dimethoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol
(3) 2-(3,4-dimethoxyphenethyl)-4-methoxyquinoline (4) (2S,3R)-6-oxo-2-((2S,3R)-3-phenyloxiran-2-yl)-3,6-dihydro-2H-pyran-3-yl cinnamate
(5) (2Z,4Z,8E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(pyrrolidin-1-yl)nona-2,4,8-trien-1-one (6) (2Z,6Z)-7-(benzo[d][1,3]dioxol-5-yl)-1-(pyrrolidin-1-yl)
hepta-2,6-dien-1-one. The dotted circle shows the presence of a Michael acceptor group (toxicophore).
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http://www.jcheminf.com/content/6/1/46structure, bioactivity and experimental details are also
captured systematically through a well-defined data struc-
ture. This platform is designed to perform analysis based
both on chemical structure and biological properties
which is the primer for any early stage drug discovery
process. To facilitate structure-based analysis, BioPhytMol
has been equipped with structure-based search options,
which may be used to compare any new compound with
the BioPhytMol database, as also with anti-TB drugs and
compounds reported in DrugBank in various categories.
These searches are expected to reveal shared/distinct
structural features of the new and known anti-TB drugs
with that of other drug-like libraries including small mole-
cules and nutraceuticals. It is interesting to observe that
there are cases where a compound has been reported toshow activity against multiple species of mycobacteria.
This feature of database may help in identification of the
structural features responsible for highly selective or
broad-spectrum activity of phytomolecules against differ-
ent mycobacterial strains. Similarly, the data and the ana-
lysis tools also enable identification of structural analogs
of reported anti-TB compounds and inhibitors of specific
drug targets in Mtb.
A revised ontology and chemical classification is also
proposed as part of systematic analysis of the compound
library. This is important for data-interoperability and
shared knowledgebase. The revised chemical classifica-
tion, though not extensive, allows the chemists to search
for compounds with specific chemical features like
aromaticity or functional groups like ketone or classes
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http://www.jcheminf.com/content/6/1/46like specific sugar moieties, thus, making the platform
useful for researchers from multiple disciplines.
A highlight of the study is the representation of multidi-
mensional data through circular graphs that allow inter-
pretation of various chemical properties with respect to
each other and with bioactivity data. CIRCOS has been
used to generate these graphs. CIRCOS is a very popular
tool among genomics and genetics community to represent
the physical map and annotation of circular genomes. For
this study, CIRCOS has been customized to represent the
chemical and biological properties of the compound library.
The same approach can be used to represent any set of
properties and is expected to aid in interpretation of multi-
dimensional data.
The real success of a database lies in its regular upda-
tion. Database updation and curation is an on-going activ-
ity. To ensure that BioPhytMol is regularly updated, a
structured-wiki platform has been designed. This platform
allows community curation of new datasets as well as
modification of the existing one for any ambiguities. The
submitters are duly acknowledged for their contribution
as each annotation or entry is author and time stamped.
The curators should register through the OSDD portal
and obtain Sysborg OpenID. This ID can then be used to
update the database through online form. However, data-
base changes are committed only when the submission is
quality checked for correctness and format. Efforts are on-
going to extend the search base of BioPhytMol as well as
to include batch query options where multiple structures
can be searched using the similarity search tool for their
corresponding similar structures.Conclusions
BioPhytMol is a drug-discovery community resource with a
database of anti-mycobacterial phytomolecules and plant
extracts. This a unique resource that encapsulates import-
ant information such as their bioactivity values (MIC), tar-
get bacteria, percentage inhibition of mycobacterial growth
and most importantly two dimensional as well as three
dimensional structures for purified anti-mycobacterial phy-
tomolecules. Structure based searching and comparison
against various drug classes aids to the features of platform
to speed up the anti-mycobacterial drug discovery.Availability and requirements
BioPhytMol is freely accessible at http://ab-openlab.csir.res.
in/biophytmol/. To access BioPhytMol, World Wide Web is
a pre-requisite. To access all features of BioPhytMol to its
optimum level, JavaScript and Java Runtime Environment
(JRE) plugin must be enabled. The raw data may be
accessed at the electronic lab notebook available at http://
sysborg2.osdd.net/group/sysborgtb/lab-notebook-details/-/
labnotebooks/show/6546.Additional file
Additional file 1: Figures: screenshots of home page and structure
search form of BioPhytMol; distribution of plants among top 35
plant families; near neighbours present amongst BioPhytMol
compounds; compounds with small structural difference but huge
MIC difference; distribution of physicochemical properties of
BioPhytMol compounds with respect to different classes of drugs;
example of proposed simplified ontology for chemical classification.
Tables: existing anti-TB drugs classified according to their drug class and
differentiated as per their origin (natural or synthetic); data structure and
definition of data fields of BioPhytMol; BioPhytMol compounds (B_mols)
showing similarity to various drug classes - anti-TB drugs (A_tb), FDA
approved nutraceutical drugs (FDA_nutra) and FDA approved small
molecule drugs (FDA_small); twenty B_mols near neighbours of two GSK
compounds (GSK146660A and GSK1996236A) with known target information;
BioPhytMol database fields mapped on the NCBO Natural products ontology
(NATPRO).
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